Shield Therapeutics (LON:STX) Shares Pass Below 50-Day Moving Average – Time to Sell?

Shield Therapeutics plc (LON:STX) passed below its 50-day moving average during trading on Friday . The stock has a 50-day moving average of GBX 3.11 ($0.04) and traded as low as GBX 3 ($0.04). Shield Therapeutics shares last traded at GBX 3.13 ($0.04), with a volume of 3,257,415 shares trading hands.

Shield Therapeutics Trading Up 0.9 %

The stock has a market cap of £30.86 million, a price-to-earnings ratio of -0.81 and a beta of 1.42. The business has a 50-day simple moving average of GBX 3.11 and a two-hundred day simple moving average of GBX 3.33. The company has a debt-to-equity ratio of 3,691.50, a quick ratio of 2.16 and a current ratio of 1.05.

Insider Buying and Selling

In related news, insider Anders Lundstrom bought 575,000 shares of the company’s stock in a transaction that occurred on Thursday, February 13th. The shares were acquired at an average price of GBX 4 ($0.05) per share, for a total transaction of £23,000 ($29,696.58). 62.16% of the stock is currently owned by corporate insiders.

About Shield Therapeutics

Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S.